AbbVie Joins Avaxia Board, Becomes An Early Investor In The Gut Therapy Biotech
This article was originally published in The Pink Sheet Daily
Executive Summary
AbbVie has been filling out its pipeline with small deals that could result in a follow-on drug to its blockbuster Humira; it’s most recent investment is in a small company doing further work in the space.